Search

Your search keyword '"Loteta, Barbara"' showing total 29 results
Start Over Author "Loteta, Barbara"
29 results on '"Loteta, Barbara"'

1. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation

Author

Martino, Massimo, Gori, Mercedes, Porto, Gaetana, Pellicano, Maria, Santoro, Ludovica, Verduci, Chiara, Canale, Filippo Antonio, Loteta, Barbara, Moscato, Tiziana, Alati, Caterina, Ieracitano, Maria Consuelo, Cuzzocrea, Amelia, Altomonte, Maria, Florenzano, Maria Teresa, Morabito, Antonella, Irrera, Giuseppe, Naso, Virginia, Pugliese, Marta, Console, Giuseppe, Ferreri, Anna, Imbalzano, Lucrezia, Tripepi, Giovanni, and Pitino, Annalisa

Published
2023
Full Text
View/download PDF

2. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide

Author

Mariotti, Jacopo, Raiola, Anna Maria, Evangelista, Andrea, Harbi, Samia, Patriarca, Francesca, Carella, Michele Angelo, Martino, Massimo, Risitano, Antonio, Busca, Alessandro, Giaccone, Luisa, Brunello, Lucia, Merla, Emanuela, Savino, Lucia, Loteta, Barbara, Console, Giuseppe, Fanin, Renato, Sperotto, Alessandra, Marano, Luana, Marotta, Serena, Frieri, Camilla, Sica, Simona, Chiusolo, Patrizia, Chabannon, Christian, Furst, Sabine, Santoro, Armando, Bacigalupo, Andrea, Bruno, Benedetto, Blaise, Didier, Mavilio, Domenico, Bramanti, Stefania, Devillier, Raynier, Angelucci, Emanuele, and Castagna, Luca

Published
2022
Full Text
View/download PDF

4. Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation

Author

Martino, Massimo, Gori, Mercedes, Porto, Gaetana, Pellicano, Maria, Santoro, Ludovica, Verduci, Chiara, Canale, Filippo Antonio, Loteta, Barbara, Moscato, Tiziana, Alati, Caterina, Ieracitano, Maria Consuelo, Cuzzocrea, Amelia, Altomonte, Maria, Florenzano, Maria Teresa, Morabito, Antonella, Irrera, Giuseppe, Naso, Virginia, Pugliese, Marta, Console, Giuseppe, Ferreri, Anna, Imbalzano, Lucrezia, Tripepi, Giovanni, and Pitino, Annalisa

Published
2023
Full Text
View/download PDF

5. First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center Study.

Author

Martino, Massimo, Gori, Mercedes, Porto, Gaetana, Policastro, Giorgia, Pitea, Martina, Sgarlata, Annalisa, Delfino, Ilaria Maria, Cogliandro, Francesca, Scopelliti, Anna, Utano, Giovanna, Pellicano, Maria, Idato, Aurora, Vincelli, Iolanda Donatella, Marafioti, Violetta, Micò, Maria Caterina, Lazzaro, Giuseppe, Loteta, Barbara, Alati, Caterina, Leanza, Giovanni, and D'Arrigo, Graziella

Subjects
THERAPEUTIC use of antineoplastic agents, STEM cell transplantation, THERAPEUTIC use of monoclonal antibodies, MULTIPLE myeloma, AUTOGRAFTS, PATIENT safety, ACADEMIC medical centers, NEUTROPHILS, MULTIPLE regression analysis, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, MULTIVARIATE analysis, BLOOD platelets, MELPHALAN, CONVALESCENCE, STATISTICS, POSTOPERATIVE period, HEMATOPOIETIC stem cells, COMPARATIVE studies, INDUCTION chemotherapy, PROPORTIONAL hazards models
Abstract

Simple Summary: Daratumumab (DARA) plus bortezomib, thalidomide, and dexamethasone (D-VTd) represent the standard of induction care in Europe for autologous stem cell transplantation (auto-SCT)-eligible, newly diagnosed multiple myeloma (NDMM) patients. This study aimed to investigate the possible impact of D-VTd induction therapy on hematopoietic engraftment after auto-SCT. Our findings indicate that patients treated with D-VTd experienced longer neutrophil and platelet engraftment times than those treated with VTd. Additionally, D-VTd treatment was associated with a higher incidence of febrile neutropenia and grade 2 or higher diarrhea. However, no significant differences were observed in the median number of days to discharge. The conclusion we can draw from our real-life study is that a four-drug induction therapy containing DARA does not impact transplant safety outcomes. Background: This real-life study aimed to investigate the possible impact of D-VTd induction therapy on hematopoietic engraftment after autologous stem cell transplantation (auto-SCT). Methods: Sixty consecutive NDMM patients received four cycles of induction therapy with D-VTd. The conditioning regimen consisted of melphalan 200 mg/m2. These patients were compared with a historical control group of 80 patients who received four cycles of VTd as induction therapy. Results: The median days to reach neutrophil and platelet engraftment significantly differed between patients treated with D-VTd (11 and 13 days, respectively) and VTd (10 and 12 days). Univariate Cox analyses show that patients treated with D-VTd had a hazard ratio of neutrophil engraftment that was 42% significantly lower than those in the VTd arm (HR: 0.58, p = 0.002), and a multivariate model confirmed this result. Patients treated with D-VTd developed FN more frequently. Univariate and multivariate logistic regressions revealed an association between D-VTd and FN. Delayed engraftment did not correlate with more extended hospitalization. No patients died in the first six months after transplantation. Conclusions: Our real-life study showed that a four-drug induction therapy containing DARA does not impact transplant safety outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience

Author

Loteta, Barbara, Paviglianiti, Annalisa, Naso, Virginia, Ferreri, Anna, Moscato, Tiziana, Console, Giuseppe, Canale, Filippo Antonio, Irrera, Giuseppe, Pugliese, Marta, Di Costanzo, Antonella, Provenzano, Pasquale Fabio, Loddo, Viviana, Porto, Gaetana, Cusumano, Giuseppa, Russo, Letteria, Meliambro, Nicola, Romeo, Valentina, Porcino, Domenico, Gallo, Salvatore, Gangemi, Tiziana, Rossetti, Antonio Maria, and Martino, Massimo

Published
2022
Full Text
View/download PDF

7. Effectiveness of biosimilar pegfilgrastim in patients with lymphoma after high-dose chemotherapy and autologous stem cell transplantation: a real-life study.

Author

Loteta, Barbara, Pitino, Annalisa, Pitea, Martina, Alati, Caterina, Tripepi, Giovanni, Mico, Maria Caterina, Pellicano, Maria, Cogliandro, Francesca, Porto, Gaetana, Policastro, Giorgia, Utano, Giovanna, Delfino, Ilaria Maria, Sgarlata, Annalisa, Scopelliti, Anna, Idato, Aurora, Laenza, Giovanni, Altomonte, Maria, D'Arrigo, Graziella, Gori, Mercedes, and Martino, Massimo

Published
2024
Full Text
View/download PDF

9. Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety

Author

Martino, Massimo, Naso, Virginia, Porto, Gaetana, Paviglianiti, Annalisa, Ferreri, Anna, Loteta, Barbara, Moscato, Tiziana, Console, Giuseppe, Gentile, Massimo, Rossi, Marco, Provenzano, Pasquale Fabio, Gori, Mercedes, Pitino, Anna Lisa, Morabito, Antonella, and Tripepi, Giovanni

Published
2020
Full Text
View/download PDF

10. Impact of donor age and kinship on clinical outcomes after T-cell–replete haploidentical transplantation with PT-Cy

Author

Mariotti, Jacopo, Raiola, Anna Maria, Evangelista, Andrea, Carella, Angelo Michele, Martino, Massimo, Patriarca, Francesca, Risitano, Antonio, Bramanti, Stefania, Busca, Alessandro, Giaccone, Luisa, Brunello, Lucia, Merla, Emanuela, Savino, Lucia, Loteta, Barbara, Console, Giuseppe, Fanin, Renato, Sperotto, Alessandra, Marano, Luana, Marotta, Serena, Frieri, Camilla, Sica, Simona, Chiusolo, Patrizia, Harbi, Samia, Furst, Sabine, Santoro, Armando, Bacigalupo, Andrea, Blaise, Didier, Angelucci, Emanuele, Mavilio, Domenico, Castagna, Luca, and Bruno, Benedetto

Published
2020
Full Text
View/download PDF

11. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant

Author

Martino, Massimo, Gori, Mercedes, Tripepi, Giovanni, Recchia, Anna Grazia, Cimminiello, Michele, Provenzano, Pasquale Fabio, Naso, Virginia, Ferreri, Anna, Moscato, Tiziana, Console, Giuseppe, Loteta, Barbara, Gallo, Giuseppe Alberto, Gentile, Massimo, Innao, Vanessa, Rossi, Marco, Morabito, Antonella, Vincelli, Iolanda Donatella, Mannina, Donato, and Pitino, Annalisa

Published
2020
Full Text
View/download PDF

12. Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts

Author

Martino, Massimo, Gori, Mercedes, Moscato, Tiziana, Naso, Virginia, Ferreri, Anna, Provenzano, Fabio, Loteta, Barbara, Sanguedolce, Maria Cristina, Console, Giuseppe, Dattola, Antonia, Pucci, Giulia, Gentile, Massimo, Morabito, Antonella, Recchia, Anna Grazia, Tripepi, Giovanni, and Pitino, Annalisa

Published
2019
Full Text
View/download PDF

13. Effectiveness of CAR-T treatment toward the potential risk of second malignancies.

Author

Martino, Massimo, Porto, Gaetana, Policastro, Giorgia, Alati, Caterina, Loteta, Barbara, Micó, Maria Caterina, Argiro', Clizia, Altomonte, Maria, Moscato, Tiziana, Labate, Demetrio, Dattola, Vincenzo, Rao, Carmelo Massimiliano, Cogliandro, Francesca, Canale, Filippo Antonio, Naso, Virginia, Filippelli, Gianfranco, Iaria, Antonino, and Pitea, Martina

Subjects
TREATMENT effectiveness, TUMOR lysis syndrome, SKIN cancer, HEMATOPOIETIC stem cell transplantation
Abstract

This document provides a list of references to studies and articles related to CAR-T cell therapy for various types of lymphoma and multiple myeloma. The studies mentioned discuss the outcomes, safety, and efficacy of CAR-T cell therapies such as lisocabtagene maraleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, and idecabtagene vicleucel. The document also includes references to studies that discuss the potential risk of secondary malignancies and other long-term effects associated with CAR-T cell therapy. [Extracted from the article]

Published
2024
Full Text
View/download PDF

14. Case Report: CAR‐T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation

Author

Canale, Filippo Antonio, primary, Pitea, Martina, additional, Alati, Caterina, additional, Porto, Gaetana, additional, Pratico, Giulia, additional, Utano, Giovanna, additional, Germanò, Jessyca, additional, Imbalzano, Lucrezia, additional, Ferreri, Anna, additional, Verduci, Chiara, additional, Santoro, Ludovica, additional, Policastro, Giorgia, additional, Loteta, Barbara, additional, Pugliese, Marta, additional, and Martino, Massimo, additional

Published
2023
Full Text
View/download PDF

15. Case Report: CAR‐T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation.

Author

Canale, Filippo Antonio, Pitea, Martina, Alati, Caterina, Porto, Gaetana, Pratico, Giulia, Utano, Giovanna, Germanò, Jessyca, Imbalzano, Lucrezia, Ferreri, Anna, Verduci, Chiara, Santoro, Ludovica, Policastro, Giorgia, Loteta, Barbara, Pugliese, Marta, and Martino, Massimo

Subjects
EXTRAMEDULLARY diseases, STEM cell transplantation, LYMPHOBLASTIC leukemia, ACUTE leukemia, CELLULAR therapy, PLASMACYTOMA
Abstract

Relapsed or refractory (r/r) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) still represent an unmet clinical need despite the new immune therapies available for these patients. We report the case of a Ph + ALL relapsed one year after allogeneic stem cell transplant. After one DLI was started CAR‐T program with brexucabtageneautoleucel, using as bridging treatment ponatinib, vincristine and prednisone. Brexu‐cel infusion was performed in 2023, without CRS or ICANS onset. One month after Brexu‐cel infusion BM aspirate and CT‐PET showed recovery of full donor chimerism, MRD negativity and complete metabolic remission. Subsequently was started maintenance with ponatinib: at last follow‐up, the patient persisted in leukemia‐free status. CAR‐T cells represent the most powerful treatment for r/r Ph + ALL but there is no consensus about the optimal bridging strategy and also regarding the management algorithm during "post CAR‐T phase". Here, we report the efficacy of ponatinib as a bridge to anti‐CD19 CAR‐T cell therapy and as post CAR‐T maintenance. Our experience suggests that a preserving approach with TKI associated to low‐dose chemotherapy can be the optimal bridging therapy prior to CAR‐T and that an "MRD‐guided" and "TKI‐based" maintenance strategy can represent the best choice for Ph + ALL which satisfactorily responds to CAR‐T. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Author

Martino, Massimo, primary, Naso, Virginia, additional, Loteta, Barbara, additional, Canale, Filippo Antonio, additional, Pugliese, Marta, additional, Alati, Caterina, additional, Musuraca, Gerardo, additional, Nappi, Davide, additional, Gaimari, Anna, additional, Nicolini, Fabio, additional, Mazza, Massimiliano, additional, Bravaccini, Sara, additional, Derudas, Daniele, additional, Martinelli, Giovanni, additional, and Cerchione, Claudio, additional

Published
2022
Full Text
View/download PDF

17. Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience

Author

Martino, Massimo, primary, Pitino, Annalisa, additional, Gori, Mercedes, additional, Bruno, Benedetto, additional, Crescimanno, Alessandra, additional, Federico, Vincenzo, additional, Picardi, Alessandra, additional, Tringali, Stefania, additional, Ingrosso, Claudia, additional, Carluccio, Paola, additional, Pastore, Domenico, additional, Musuraca, Gerardo, additional, Paviglianiti, Annalisa, additional, Vacca, Adriana, additional, Serio, Bianca, additional, Storti, Gabriella, additional, Mordini, Nicola, additional, Leotta, Salvatore, additional, Cimminiello, Michele, additional, Prezioso, Lucia, additional, Loteta, Barbara, additional, Ferreri, Anna, additional, Colasante, Fabrizia, additional, Merla, Emanuela, additional, Giaccone, Luisa, additional, Busca, Alessandro, additional, Musso, Maurizio, additional, Scalone, Renato, additional, Di Renzo, Nicola, additional, Marotta, Serena, additional, Mazza, Patrizio, additional, Musto, Pellegrino, additional, Attolico, Immacolata, additional, Selleri, Carmine, additional, Canale, Filippo Antonio, additional, Pugliese, Marta, additional, Tripepi, Giovanni, additional, Porto, Gaetana, additional, Martinelli, Giovanni, additional, Carella, Angelo Michele, additional, and Cerchione, Claudio, additional

Published
2021
Full Text
View/download PDF

18. Identifying and Managing CAR T-Cell–Mediated Toxicities: on behalf of an Italian CAR-T Multidisciplinary Team

Author

Martino, Massimo, primary, Macheda, Sebastiano, additional, Aguglia, Umberto, additional, Arcudi, Luciano, additional, Pucci, Giulia, additional, Martino, Bruno, additional, Altomonte, Maria, additional, Rossetti, Antonio Maria, additional, Cusumano, Giuseppa, additional, Russo, Letteria, additional, Imbalzano, Lucrezia, additional, Stelitano, Caterina, additional, Alati, Caterina, additional, Germano’, Jessyca, additional, Labate, Demetrio, additional, Amalfi, Vincenzo, additional, Florenzano, Maria Teresa, additional, Morabito, Antonella, additional, Borzumati, Vittoria, additional, Dattola, Vincenzo, additional, Gattuso, Caterina, additional, Moschella, Antonio, additional, Quattrone, Domenico, additional, Curmaci, Francesco, additional, Franzutti, Claudio, additional, Scappatura, Giuseppe, additional, Rao, Carmelo Massimiliano, additional, Loddo, Viviana, additional, Pontari, Antonella, additional, Pellicano’, Maria, additional, Surace, Rosangela, additional, Sanguedolce, Cristina, additional, Naso, Virginia, additional, Ferreri, Anna, additional, Irrera, Giuseppe, additional, Console, Giuseppe, additional, Moscato, Tiziana, additional, Loteta, Barbara, additional, Canale, Filippo Antonio, additional, Trimarchi, Alfonso, additional, Monteleone, Renza, additional, Said, Al Sayyad, additional, Cirrone, Frank, additional, and Bruno, Benedetto, additional

Published
2021
Full Text
View/download PDF

19. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience

Author

Loteta, Barbara, primary, Paviglianiti, Annalisa, additional, Naso, Virginia, additional, Ferreri, Anna, additional, Moscato, Tiziana, additional, Console, Giuseppe, additional, Canale, Filippo Antonio, additional, Irrera, Giuseppe, additional, Pugliese, Marta, additional, Di Costanzo, Antonella, additional, Provenzano, Pasquale Fabio, additional, Loddo, Viviana, additional, Porto, Gaetana, additional, Cusumano, Giuseppa, additional, Russo, Letteria, additional, Meliambro, Nicola, additional, Romeo, Valentina, additional, Porcino, Domenico, additional, Gallo, Salvatore, additional, Gangemi, Tiziana, additional, Rossetti, Antonio Maria, additional, and Martino, Massimo, additional

Published
2021
Full Text
View/download PDF

20. Letermovir Prophylaxis For Cytomegalovirus Reactivation in Allogeneic Stem Cell Transplantation: A Multicenter Italian Real-world Experience

Author

Paviglianiti, Annalisa, Pitino, Annalisa, Carella, Angelo Michele, Bruno, Benedetto, Crescimanno, Alessandra, Federico, Vincenzo, Picardi, Alessandra, Tringali, Stefania, Ingrosso, Claudia, Carluccio, Paola, Pastore, Domenico, Vacca, Adriana, Serio, Bianca, Storti, Gabriella, Mordini, Nicola, Leotta, Salvatore, Cimminiello, Michele, Prezioso, Lucia, Loteta, Barbara, Ferreri, Anna, Colasante, Fabrizia, Merla, Emanuela, Giaccone, Luisa, Busca, Alessandro, Musso, Maurizio, Scalone, Renato, Di Renzo, Nicola, Marotta, Serena, Mazza, Patrizio, Musto, Pellegrino, Attolico, Immacolata, Selleri, Carmine, Gori, Mercedes, Tripepi, Giovanni, Porto, Gaetana, and Massimo Martino

Published
2021

21. CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma

Author

Martino, Massimo, primary, Canale, Filippo Antonio, additional, Alati, Caterina, additional, Vincelli, Iolanda Donatella, additional, Moscato, Tiziana, additional, Porto, Gaetana, additional, Loteta, Barbara, additional, Naso, Virginia, additional, Mazza, Massimiliano, additional, Nicolini, Fabio, additional, Ghelli Luserna di Rorà, Andrea, additional, Simonetti, Giorgia, additional, Ronconi, Sonia, additional, Ceccolini, Michela, additional, Musuraca, Gerardo, additional, Martinelli, Giovanni, additional, and Cerchione, Claudio, additional

Published
2021
Full Text
View/download PDF

23. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant

Author

Martino, Massimo, primary, Gori, Mercedes, additional, Tripepi, Giovanni, additional, Recchia, Anna Grazia, additional, Cimminiello, Michele, additional, Provenzano, Pasquale Fabio, additional, Naso, Virginia, additional, Ferreri, Anna, additional, Moscato, Tiziana, additional, Console, Giuseppe, additional, Loteta, Barbara, additional, Gallo, Giuseppe Alberto, additional, Gentile, Massimo, additional, Innao, Vanessa, additional, Rossi, Marco, additional, Morabito, Antonella, additional, Vincelli, Iolanda Donatella, additional, Mannina, Donato, additional, and Pitino, Annalisa, additional

Published
2019
Full Text
View/download PDF

24. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials

Author

Martino, Massimo, primary, Rossi, Marco, additional, Ferreri, Anna, additional, Loteta, Barbara, additional, Morabito, Antonella, additional, Moscato, Tiziana, additional, Console, Giuseppe, additional, Innao, Vanessa, additional, Naso, Virginia, additional, Provenzano, Pasquale Fabio, additional, Recchia, Anna Grazia, additional, and Gentile, Massimo, additional

Published
2019
Full Text
View/download PDF

25. The use of ibrutinib before and after allogeneic stem cell transplantation

Author

Martino, Massimo, primary, Ferreri, Anna, additional, Naso, Virginia, additional, Moscato, Tiziana, additional, Loteta, Barbara, additional, Gentile, Massimo, additional, Morabito, Antonella, additional, Provenzano, Fabio, additional, Cimminiello, Michele, additional, Carella, Angelo Michele, additional, Console, Giuseppe, additional, and Recchia, Anna Grazia, additional

Published
2019
Full Text
View/download PDF

26. Identifying and managing CAR T-cell–mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team

Author

Martino, Massimo, Macheda, Sebastiano, Aguglia, Umberto, Arcudi, Luciano, Pucci, Giulia, Martino, Bruno, Altomonte, Maria, Rossetti, Antonio Maria, Cusumano, Giuseppa, Russo, Letteria, Imbalzano, Lucrezia, Stelitano, Caterina, Alati, Caterina, Germano’, Jessyca, Labate, Demetrio, Amalfi, Vincenzo, Florenzano, Maria Teresa, Morabito, Antonella, Borzumati, Vittoria, Dattola, Vincenzo, Gattuso, Caterina, Moschella, Antonio, Quattrone, Domenico, Curmaci, Francesco, Franzutti, Claudio, Scappatura, Giuseppe, Rao, Carmelo Massimiliano, Loddo, Viviana, Pontari, Antonella, Pellicano’, Maria, Surace, Rosangela, Sanguedolce, Cristina, Naso, Virginia, Ferreri, Anna, Irrera, Giuseppe, Console, Giuseppe, Moscato, Tiziana, Loteta, Barbara, Canale, Filippo Antonio, Trimarchi, Alfonso, Monteleone, Renza, Al Sayyad, Said, Cirrone, Frank, and Bruno, Benedetto

Abstract

ABSTRACTIntroductionChimeric antigen receptor (CAR)-T-cell therapy is a new treatment for patients with hematologic malignancies in which other therapies have failed.Areas coveredThe review provides an overview for recognizing and managing the most acute toxicities related to CAR-T cells.Expert opinionThe development of immune-mediated toxicities is a common challenge of CAR-T therapy. The mechanism that determines this toxicity is still unclear, although an unfavorable tumor microenvironment and a pro-inflammatory state put patients at risk. The monitoring, diagnosis, and treatment of post-CAR-T toxicities must be determined and based on international guidelines and internal clinical practice. It is urgent to identify biomarkers that can identify patients at greater risk of developing complications. The adoption of consistent grading criteria is necessary to improve toxicity management strategies continually. The first-line therapy consists of supportive care and treatment with tocilizumab or corticosteroids. An early start of cytokine blockade therapies could mitigate toxicity. The plan will include cytokine release prophylaxis, a risk-adapted treatment, prevention of on-target/off-tumor effect, and a switch on/off CAR-T approach.

Published
2022
Full Text
View/download PDF

27. Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review

Author

Mannina, Donato and Loteta, Barbara

Subjects
Article Subject, immune system diseases, hemic and lymphatic diseases
Abstract

Mantle cell lymphoma (MCL) accounts for about 5% of all lymphomas. Its clinical and histological features are heterogeneous. After a frequently good initial response, the disease generally and repeatedly relapses and finally the outcome is poor. Particularly severe is the prognosis of the rare occurrence of CNSi (Central Nervous System involvement). Ibrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), has shown strong activity in relapsing patients with Chronic Lymphocytic Leukemia (CLL) and MCL. Few reports are available about treatment with ibrutinib of patients presenting CNSi by lymphoproliferative diseases (LPD). In all of them, ibrutinib, at the dosage between 420 and 560 mg/day, showed an impressive effectiveness. Here we describe a case of MCL with CNS relapse showing an excellent response to ibrutinib administered at the unusual dose of 280 mg/day because of concomitant treatment of cardiological disease.

Published
2017
Full Text
View/download PDF

29. [Lipid profile in hematologic neoplasms].

Author

Musolino C, Calabrò L, Bellomo G, Cincotta M, Di Giacomo V, Pezzano C, Loteta B, Rizzo V, Guglielmo S, and Alonci A

Subjects
Female, Humans, Male, Middle Aged, Apolipoproteins blood, Cholesterol blood, Hematologic Neoplasms blood
Abstract

Background and Objective: Abnormal blood lipid profiles have been reported in human malignancies. So, it is likely an overall involvement of tumoral cell metabolism. The aim of this study was to evaluate clinico-biological implications of altered lipid profiles in oncohaematologic patients., Design and Methods: The plasma lipids, lipoproteins and apolipoproteins were determined at the time of diagnosis in 48 previously untreated patients (35M, 13F, median age 60 years), 11 with multiple myeloma (MM), 11 with non-Hodgkin's lymphoma (NHL), 11 with acute leukemia (AL), 10 with chronic myeloproliferative disorders (CMD) and 5 with B-chronic lymphocytic leukemia (B-CLL). The results were correlated with known prognostic serum markers, such as lactate dehydrogenase (LDH), beta-2-microglobulin (beta 2m), and soluble molecule ICAM1 (sICAM1)., Results: Altered blood lipid profiles were observed in all concohaematologic patients. Statistically significant values included reduced cholesterol (155 +/- 47.36 vs 205 +/- 35 mg/dl; p < 0.001), HDL-C (30.47 +/- 13.36 vs 45 +/- 10 mg/dl; p < 0.003) and apo A (118.86 +/- 49.98 vs 182.69 mg/dl; p < 0.0001) levels. No correlations were found between cholesterol levels and clinico-biological features representative of tumor mass (LDH, beta 2m, sICAM-1). A significant increase of cholesterol levels was observed in all patients responding to therapy., Interpretation and Conclusion: These results support the idea that the cholesterol, its fractions and the apolipoproteins determinations might be considered as useful biochemical and prognostic markers in hematologic neoplasms.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results